Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NICOX SA
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
July 1, 2026
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
June 18, 2026
Nicox Provides Full Year 2025 Financial Results and Corporate Update
May 8, 2026
Nicox Provides Full Year 2025 Financial Results and Corporate Update
April 30, 2026
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
April 20, 2026
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
February 24, 2026
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
February 16, 2026
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
February 12, 2026